Kings Point Capital Management’s Biogen BIIB Stock Holding History

Kings Point Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20	Closed	-$56K	–	458
2019 Q4	$56K	Buy	+20	New	+$5.55K	0.01%	301

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Kings Point Capital Management's BIIB Position: Q2 2021 in Review

Kings Point Capital Management sold out of Biogen (BIIB) in Q2 2021, closing a stake of 510 shares — an estimated $143K sold.

Kings Point Capital Management first reported a position in BIIB in Q3 2014 and held it in 11 quarters. The position peaked at $201K in Q3 2020. 1,105 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Kings Point Capital Management reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Kings Point Capital Management sold 510 Biogen shares in Q2 2021, an estimated $143K.
Kings Point Capital Management first reported a position in Biogen in Q3 2014 and held it in 11 quarters.
Kings Point Capital Management's Biogen position peaked at $201K in Q3 2020.
1,105 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Kings Point Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.